Kenvue Stock Hits One-Year Low After Report Says HHS Will Link Tylenol Use in Pregnancy to Autism Risk
Synopsis
According to a report by The Wall Street Journal, the Department of Health and Human Services is likely to release its findings later this month.
Tylenol maker Kenvue (KVUE) dropped to a one-year low in afternoon trade on Friday after reports surfaced that Health Secretary Robert F. Kennedy Jr. intends to link prenatal use of the drug to autism.
Kenvue’s stock tumbled more than 11% to $18.11, its lowest level since August 2024. On Stocktwits, retail sentiment around the company fell into ‘bearish’ territory from ‘neutral’ a day ago.
According to a report by The Wall Street Journal, the Department of Health and Human Services (HHS) is likely to release its findings later this month. The upcoming Health Department report is expected to link autism risk to low folate levels and Tylenol use during pregnancy, people familiar with the matter told the publication.
Get updates to this developing story directly on Stocktwits.<
Read also: Bessent Reportedly Says Fed Must Change Course To Preserve Independence
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.